With the development number ND-L02-s0201, the intravenous preparation of a nucleic acid medicine is a siRNA, embedded in vitamin A containing liposome preparation, that suppresses the expression of the HSP 47 gene. The HSP 47 gene regulates collagen production and secretion responsible for fibrosis and is considered as a target molecule for a wide range of organ fibrosis such as liver cirrhosis and idiopathic pulmonary fibrosis. To date, Nitto Denko has conducted phase Ib for patients with liver cirrhosis in Japan and Bulgaria, Phase Ib / II for patients with cirrhosis due to nonalcoholic steatohepatitis (NASH) and hepatitis C, and Phase Ib in Japan. Under a license agreement between Nitto Denko and Bristol-Myers Squibb (BMS), BMS has started phase II in 165 patients with liver cirrhosis and liver fibrosis in the United States from February 2018 in the US (BMS-986263).
Source: Nitto Denko news release, March 5, 2018
Request a quote for deeper information from